Eli Lilly and Alexandria Real Estate Equities are among the investors in a round that took the protein drug developer’s total funding to over $150m.

Lycia Therapeutics, a US-based developer of therapies targeting extra-cellular proteins, has closed a $70m series B round featuring pharmaceutical company Eli Lilly and life sciences real estate investment trust Alexandria Real Estate Equities.

The round was led by Redmile Group and filled out by Versant Ventures, Cowen Healthcare Investments, Invus and RTW Investments, while Alexandria Real Estate Equities participated through its strategic investment arm Alexandria Venture Investments.

Founded in 2019 through venture capital firm Versant Ventures’ Inception Therapeutics Discovery Engine,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn